Understanding immunE-related toXicities by multifACeT Profiling
NCT05331066 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-10-01
Summary
A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.
Conditions
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Principal Investigators
-
Samra Turajlic · Royal Marsden NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-06
- Primary Completion
- 2028-04-06
- Completion
- 2028-04-06
Countries
- United Kingdom
Study Locations
More Related Trials
-
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3
-
HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC
NCT05834686 ·Status: UNKNOWN
-
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
NCT05318339 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086 ·Status: RECRUITING ·Phase: PHASE3
-
The Rechallenge of ADCs in MBC Patients
NCT05571618 ·Status: ACTIVE_NOT_RECRUITING
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
NCT06784921 ·Status: RECRUITING
-
A Study of A166 in Patients With Advanced Solid Malignant Tumors
NCT05311397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
NCT06331169 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
NCT03084939 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
NCT03153163 ·Status: COMPLETED ·Phase: PHASE1
-
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
NCT02025712 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
NCT06332131 ·Status: ENROLLING_BY_INVITATION
-
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348 ·Status: RECRUITING ·Phase: PHASE1
-
Irinotecan for Advanced and Metastatic Breast Cancer
NCT03562390 ·Status: UNKNOWN ·Phase: PHASE2
-
Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients
NCT01779531 ·Status: UNKNOWN
-
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
NCT03430466 ·Status: TERMINATED ·Phase: PHASE2
-
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
NCT07023861 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
NCT04927884 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
NCT01617668 ·Status: COMPLETED ·Phase: PHASE2
-
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
NCT01088893 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
NCT03515798 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2